ProtAffin AG Starts Phase 1 Study for Lead Product PA401 in Inflammatory Lung Disease
Published: Jun 27, 2012
GRAZ, Austria & LONDON--(BUSINESS WIRE)--ProtAffin AG, a biotechnology company developing a novel class of next-generation biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has started dosing healthy volunteers in a Phase 1 clinical study in the UK with its novel investigational anti-inflammatory product, PA401. PA401 is a modified form of the human chemokine IL-8. Human IL-8 (CXCL8) is a chemokine produced by macrophages and other cells and its primary function is the attraction of neutrophils to sites of acute and chronic inflammation. PA401 acts as a potent, targeted anti-inflammatory protein preventing the infiltration of neutrophils which is a hallmark of many respiratory diseases including chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).